RARE - Ultragenyx Pharmaceutical Inc Stock Price, Fair Value and News

44.15USD+1.78 (+4.20%)Delayed as of 22 Apr 2024, 01:12 pm ET

Market Summary

USD44.15+1.78

Delayedas of 22 Apr 2024, 01:12 pm

4.20%

RARE Stock Price

View Fullscreen

RARE RSI Chart

RARE Valuation

Market Cap

3.5B

Price/Earnings (Trailing)

-5.75

Price/Sales (Trailing)

8.03

EV/EBITDA

-5.62

Price/Free Cashflow

-6.72

RARE Price/Sales (Trailing)

RARE Profitability

Operating Margin

89.59%

EBT Margin

-140.12%

Return on Equity

-220.26%

Return on Assets

-40.69%

Free Cashflow Yield

-14.88%

RARE Fundamentals

RARE Revenue

Revenue (TTM)

434.2M

Rev. Growth (Yr)

23.27%

Rev. Growth (Qtr)

29.92%

RARE Earnings

Earnings (TTM)

-606.6M

Earnings Growth (Yr)

18.86%

Earnings Growth (Qtr)

22.84%

Breaking Down RARE Revenue

52 Week Range

33.5854.98

(Low)(High)

Last 7 days

-9.8%

Last 30 days

-9.9%

Last 90 days

-5%

Trailing 12 Months

2.7%

How does RARE drawdown profile look like?

RARE Financial Health

Current Ratio

2.61

RARE Investor Care

Shares Dilution (1Y)

17.26%

Diluted EPS (TTM)

-8.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	383.9M	402.9M	410.2M	434.2M
2022	331.9M	334.3M	343.4M	363.3M
2021	334.1M	359.4M	359.6M	351.4M
2020	121.9M	159.4M	215.1M	271.0M
2019	59.0M	70.3M	84.4M	103.7M
2018	13.0M	25.8M	37.3M	51.5M
2017	0	0	331.0K	2.4M
2016	0	322.0K	370.0K	282.0K
2014	0	331.0K	0	0
2013	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ultragenyx Pharmaceutical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 18, 2024	crombez eric	sold	-6,262	44.1	-142	evp and chief medical officer
Apr 16, 2024	huizenga theodore alan	sold (taxes)	-592	42.31	-14.00	svp, chief accounting officer
Mar 11, 2024	kassberg thomas richard	sold	-574,644	49.93	-11,509	cbo & evp
Mar 07, 2024	fust matthew k	sold	-620,443	50.8768	-12,195	-
Mar 01, 2024	pinion john richard	sold (taxes)	-3,221	53.69	-60.00	see remarks
Mar 01, 2024	harris erik	sold	-256,328	53.76	-4,768	evp & chief commercial officer
Mar 01, 2024	kakkis emil d	sold (taxes)	-935,119	53.69	-17,417	president & ceo
Mar 01, 2024	huizenga theodore alan	acquired	-	-	13,950	svp, chief accounting officer
Mar 01, 2024	huang dennis karl	sold (taxes)	-25,234	53.69	-470	see remarks
Mar 01, 2024	harris erik	acquired	-	-	20,357	evp & chief commercial officer

Which funds bought or sold RARE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	67.66	60,282	154,917	-%
Apr 18, 2024	MV CAPITAL MANAGEMENT, INC.	new	-	47.00	47.00	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	40.02	621,107	2,312,880	0.12%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	added	3.37	2,733	298,069	-%
Apr 15, 2024	JANICZEK WEALTH MANAGEMENT, LLC	unchanged	-	-23.00	934	-%
Apr 15, 2024	Sunbelt Securities, Inc.	unchanged	-	-98.00	4,015	-%
Apr 12, 2024	First PREMIER Bank	new	-	2,000	2,000	-%
Apr 12, 2024	DNB Asset Management AS	new	-	467,780	467,780	-%
Apr 11, 2024	Signature Resources Capital Management, LLC	unchanged	-	-	717	-%
Apr 09, 2024	WOODSTOCK CORP	added	38.01	133,951	519,380	0.05%

Are Funds Buying or Selling RARE?

Are funds buying RARE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RARE

No. of Funds

Unveiling Ultragenyx Pharmaceutical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	4.2%	3,453,460	SC 13G/A
Feb 14, 2024	rtw investments, lp	8.4%	6,887,086	SC 13G/A
Feb 13, 2024	vanguard group inc	10.56%	8,673,432	SC 13G/A
Feb 13, 2024	sands capital management, llc	5.0%	4,118,008	SC 13G
Feb 08, 2024	wellington management group llp	5.38%	4,415,029	SC 13G/A
Jan 29, 2024	blackrock inc.	6.4%	5,238,400	SC 13G/A
Sep 11, 2023	vanguard group inc	10.12%	7,236,523	SC 13G/A
Feb 14, 2023	rtw investments, lp	5.7%	3,966,915	SC 13G
Feb 14, 2023	price t rowe associates inc /md/	5.8%	4,096,388	SC 13G/A
Feb 09, 2023	vanguard group inc	9.09%	6,374,230	SC 13G/A

Recent SEC filings of Ultragenyx Pharmaceutical Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	4	Insider Trading
Apr 18, 2024	4	Insider Trading
Apr 15, 2024	8-K	Current Report
Mar 12, 2024	4	Insider Trading
Mar 11, 2024	144	Notice of Insider Sale Intent
Mar 11, 2024	4	Insider Trading
Mar 07, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Ultragenyx Pharmaceutical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Ultragenyx Pharmaceutical Inc News

Latest updates

Ultragenyx Pharmaceutical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	29.9%	127,392,000	98,052,000	108,309,000	100,496,000	103,348,000	90,703,000	89,343,000	79,935,000	83,389,000	81,647,000	86,975,000	99,395,000	91,542,000	81,470,000	61,709,000	36,309,000	35,593,000	25,800,000	24,149,000	18,172,000	16,261,000
Cost Of Revenue	9.7%	12,051,000	10,987,000	9,914,000	12,257,000	5,319,000	8,631,000	8,270,000	6,100,000	3,509,000	4,175,000	3,136,000	5,188,000	5,481,000	2,348,000	1,803,000	-3,503,000	5,107,000	2,683,000	766,000	452,000	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	169,751,000	205,964,000	187,623,000	131,785,000	124,764,000	156,974,000	130,045,000	143,833,000	136,623,000	117,386,000	106,601,000
S&GA Expenses	2.6%	76,833,000	74,917,000	81,403,000	76,646,000	72,849,000	69,841,000	68,137,000	67,312,000	59,431,000	53,883,000	53,410,000	53,258,000	51,042,000	42,123,000	42,252,000	47,516,000	41,877,000	41,006,000	39,812,000	38,829,000	34,476,000
R&D Expenses	2.1%	160,557,000	157,245,000	164,949,000	165,698,000	170,808,000	237,297,000	154,529,000	143,155,000	123,013,000	113,417,000	113,205,000	147,518,000	175,080,500	87,314,000	80,709,000	25,000,000	83,061,000	100,144,000	96,045,000	78,105,000	71,618,000
EBITDA Margin	10.1%	-1.34	-1.49	-1.72	-1.81	-1.88	-1.90	-1.46	-1.37	-1.25	-0.95	-0.94	-0.57	-	-	-	-	-	-	-	-	-
Income Taxes	-669.5%	-3,702,000	650,000	732,000	495,000	-1,451,000	6,287,000	302,000	558,000	20,000	182,000	463,000	379,000	70,000	313,000	415,000	409,000	2,561,000	293,000	213,000	216,000	126,000
Earnings Before Taxes	20.2%	-126,892,000	-158,999,000	-159,096,000	-163,477,000	-153,284,000	-238,819,000	-157,860,000	-151,762,000	-122,438,000	-72,816,000	-121,965,000	-135,762,000	-23,941,000	-68,532,000	25,730,000	-118,616,000	-91,244,000	-112,701,000	-98,959,000	-96,540,000	-87,700,000
EBT Margin	9.5%	-1.40	-1.55	-1.77	-1.86	-1.93	-1.95	-1.51	-1.41	-1.29	-0.99	-0.97	-0.61	-	-	-	-	-	-	-	-	-
Net Income	22.8%	-123,190,000	-159,649,000	-159,828,000	-163,972,000	-151,833,000	-245,106,000	-158,162,000	-152,320,000	-122,458,000	-72,998,000	-122,428,000	-136,141,000	-24,011,000	-68,845,000	25,315,000	-119,025,000	-93,805,000	-112,994,000	-99,172,000	-96,756,000	-87,826,000
Net Income Margin	9.8%	-1.40	-1.55	-1.79	-1.87	-1.95	-1.97	-1.51	-1.42	-1.29	-0.99	-0.98	-0.61	-	-	-	-	-	-	-	-	-
Free Cashflow	29.7%	-85,504,000	-121,569,000	-130,099,000	-181,901,000	-117,312,000	-121,391,000	-108,180,000	-149,705,000	-70,392,000	-80,209,000	-85,427,000	-175,760,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	20.4%	1,491	1,238	1,311	1,383	1,545	1,618	1,321	1,384	1,522	1,485	1,512	1,598	1,760	1,268	1,314	1,233	1,135	880	959	1,008	720
Current Assets	22.2%	732	599	702	766	884	1,013	679	708	857	847	949	1,071	1,295	872	906	894	851	613	699	787	522
Cash Equivalents	194.3%	214	73.00	102	86.00	133	392	160	154	308	198	291	384	714	197	336	298	434	123	131	270	113
Inventory	6.8%	34.00	32.00	28.00	27.00	27.00	22.00	21.00	18.00	16.00	15.00	15.00	12.00	13.00	14.00	11.00	11.00	12.00	14.00	14.00	11.00	7.00
Net PPE	-2.1%	291	297	289	278	260	235	207	177	141	119	105	88.00	74.00	49.00	48.00	48.00	44.00	32.00	25.00	22.00	20.00
Goodwill	0%	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00
Liabilities	0.8%	1,216	1,206	1,182	1,163	1,193	1,150	643	588	600	551	540	543	605	602	618	624	482	153	139	121	111
Current Liabilities	10.4%	280	254	244	218	261	227	221	167	181	136	127	127	190	201	220	197	103	90.00	75.00	67.00	75.00
Shareholder's Equity	768.4%	275	32.00	129	220	352	469	678	796	923	934	972	1,055	1,154	666	696	609	654	727	820	887	609
Retained Earnings	-3.8%	-3,387	-3,264	-3,104	-2,944	-2,781	-2,629	-2,384	-2,225	-2,073	-1,951	-1,878	-1,755	-1,619	-1,595	-1,526	-1,552	-1,433	-1,339	-1,226	-1,127	-1,030
Additional Paid-In Capital	11.0%	3,662	3,298	3,237	3,169	3,140	3,108	3,071	3,029	2,997	2,885	2,850	2,810	2,773	2,261	2,221	2,163	2,087	2,066	2,046	2,014	1,640
Shares Outstanding	14.1%	82.00	72.00	71.00	71.00	70.00	70.00	70.00	70.00	68.00	68.00	67.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	3,100	-	-	-	3,300	-	-	-	6,500	-	-	-	4,700	-	-	-	2,700	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	28.8%	-83.90	-117	-116	-156	-90.34	-95.34	-77.26	-117	-54.34	-59.65	-65.36	-159	-62.45	-61.97	87.00	-95.15	-72.04	-88.51	-89.06	-95.77	-55.85
Share Based Compensation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00	20.00	22.00	20.00	21.00
Cashflow From Investing	-266.4%	-107	64.00	99.00	111	-171	-161	79.00	-37.36	69.00	-40.76	-41.25	-182	98.00	-95.76	-86.14	-95.12	67.00	79.00	-58.43	-101	74.00
Cashflow From Financing	1210.2%	331	25.00	33.00	-0.72	2.00	492	6.00	2.00	86.00	8.00	13.00	13.00	490	19.00	36.00	56.00	315	1.00	9.00	354	12.00

RARE Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 434,249	$ 363,329	$ 351,406
Operating expenses:
Cost of sales	45,209	28,320	16,008
Research and development	648,449	705,789	497,153
Selling, general and administrative	309,799	278,139	219,982
Total operating expenses	1,003,457	1,012,248	733,143
Loss from operations	(569,208)	(648,919)	(381,737)
Interest income	26,688	11,074	1,928
Change in fair value of equity investments	397	(19,299)	(42,063)
Non-cash interest expense on liabilities for sales of future royalties	(66,004)	(43,015)	(29,422)
Other expense	(337)	(1,566)	(1,687)
Loss before income taxes	(608,464)	(701,725)	(452,981)
Benefit from (provision for) income taxes	1,825	(5,696)	(1,044)
Net loss	$ (606,639)	$ (707,421)	$ (454,025)
Net loss per share, basic	$ (8.25)	$ (10.12)	$ (6.7)
Net loss per share, diluted	$ (8.25)	$ (10.12)	$ (6.7)
Shares used in computing net loss per share, Basic	73,543,862	69,914,225	67,795,540
Shares used in computing net loss per share, Diluted	73,543,862	69,914,225	67,795,540
Product sales
Revenues:
Total revenues	$ 180,413	$ 118,927	$ 77,017
Royalty revenue
Revenues:
Total revenues	182,652	21,692	17,951
Collaboration and license
Revenues:
Total revenues	$ 71,184	$ 222,710	$ 256,438

RARE Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 213,584	$ 132,944
Marketable debt securities	363,625	614,818
Accounts receivable, net	73,390	40,445
Inventory	33,969	26,766
Other assets	47,616	68,926
Total current assets	732,184	883,899
Property, plant, and equipment, net	290,566	259,726
Marketable debt securities	199,901	148,970
Intangible assets, net	166,271	160,105
Goodwill	44,406	44,406
Other assets	57,685	48,338
Total assets	1,491,013	1,545,444
Current liabilities:
Accounts payable	42,114	43,274
Accrued liabilities	196,486	204,678
Contract liabilities	0	1,479
Lease liabilities	12,595	11,779
Liabilities for sales of future royalties	29,242	0
Total current liabilities	280,437	261,210
Lease liabilities	30,574	19,814
Deferred tax liabilities	30,058	31,667
Liabilities for sales of future royalties	862,325	875,439
Other liabilities	12,205	4,820
Total liabilities	1,215,599	1,192,950
Commitments and contingencies (Notes 9 and 15)
Stockholders’ equity:
Preferred stock, par value of $0.001 per share - 25,000,000 shares authorized; nil outstanding in 2023 and in 2022	0	0
Common stock, par value of $0.001 per share - 250,000,000 shares authorized;outstanding - 82,315,590 in 2023 and 70,197,297 in 2022	82	70
Treasury stock, at cost, 9,559 in 2023 and nil in 2022	(432)	0
Deferred compensation obligation	432	0
Additional paid-in capital	3,662,346	3,140,019
Accumulated other comprehensive income (loss)	647	(6,573)
Accumulated deficit	(3,387,661)	(2,781,022)
Total stockholders’ equity	275,414	352,494
Total liabilities and stockholders’ equity	$ 1,491,013	$ 1,545,444

About Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

CEO	Dr. Emil D. Kakkis M.D., Ph.D.
WEBSITE	ultragenyx.com
INDUSTRY	Biotechnology
EMPLOYEES	1311

Ultragenyx Pharmaceutical Inc Frequently Asked Questions

What is the ticker symbol for Ultragenyx Pharmaceutical Inc? What does RARE stand for in stocks?

RARE is the stock ticker symbol of Ultragenyx Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ultragenyx Pharmaceutical Inc (RARE)?

As of Fri Apr 19 2024, market cap of Ultragenyx Pharmaceutical Inc is 3.49 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RARE stock?

You can check RARE's fair value in chart for subscribers.

What is the fair value of RARE stock?

You can check RARE's fair value in chart for subscribers. The fair value of Ultragenyx Pharmaceutical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ultragenyx Pharmaceutical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RARE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ultragenyx Pharmaceutical Inc a good stock to buy?

The fair value guage provides a quick view whether RARE is over valued or under valued. Whether Ultragenyx Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact Ultragenyx Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RARE.

What is Ultragenyx Pharmaceutical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, RARE's PE ratio (Price to Earnings) is -5.75 and Price to Sales (PS) ratio is 8.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RARE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ultragenyx Pharmaceutical Inc's stock?

In the past 10 years, Ultragenyx Pharmaceutical Inc has provided 0.002 (multiply by 100 for percentage) rate of return.